<DOC>
	<DOCNO>NCT00511147</DOCNO>
	<brief_summary>Idiopathic ( immune ) thrombocytopenic purpura ( ITP ) autoimmune disorder characterize platelet destruction thrombocytopenia ( peripheral blood platelet count &lt; 150 x 10 ( 9 ) /L ) . IVIG therapy useful patient platelet count raise either due bleeding sign , bleed predict ( e.g. , surgery parturition ) . The primary goal treatment maintain platelet count hemostatic level . This study test safety efficacy IGIV3I Grifols 10 % treatment patient chronic ITP .</brief_summary>
	<brief_title>IGIV Study Chronic ITP Patients Ages 3-70</brief_title>
	<detailed_description />
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Eligible subject must 3 70 year age Must diagnosis chronic ITP Must platelet count â‰¤ 20 x 10 ( 9 ) /L</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>IVIG</keyword>
	<keyword>ITP</keyword>
</DOC>